HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.

Abstract
Post-transplantation cyclophosphamide (PTCy) is an effective strategy to prevent graft-versus-host disease (GVHD) after haploidentical haematopoietic cell transplantation (HCT). We determined the efficacy of PTCy-based GVHD prophylaxis in human leucocyte antigen (HLA)-mismatched unrelated donor (MMUD) HCT. We analysed 113 adult patients with high-risk haematological malignancies who underwent one-antigen MMUD transplantation between 2009 and 2013. Of these, 41 patients received PTCy, tacrolimus and mycophenolate mofetil (MMF) for GVHD prophylaxis; 72 patients received conventional prophylaxis with anti-thymocyte globulin, tacrolimus and methotrexate. Graft source was primarily bone marrow (83% PTCy vs. 63% conventional group). Incidence of grade II-IV (37% vs. 36%, P = 0·8) and grade III-IV (17% vs. 12%, P = 0·5) acute GVHD was similar at day 100. However, the incidence of grade II-IV acute GVHD by day 30 was significantly lower in the PTCy group (0% vs. 15%, P = 0·01). Median time to neutrophil (18 days vs. 12 days, P < 0·001) and platelet (25·5 days vs. 18 days, P = 0·05) engraftment was prolonged in PTCy group. Rates of graft failure, chronic GVHD, 2-year non-relapse mortality, relapse, progression-free survival or overall survival were similar. Our results demonstrate that PTCy, tacrolimus and MMF for GVHD prophylaxis is safe and produced similar results as conventional prophylaxis in patients with one antigen HLA-MMUD HCT.
AuthorsRohtesh S Mehta, Rima M Saliba, Julianne Chen, Gabriela Rondon, Aimee E Hammerstrom, Amin Alousi, Muzaffar Qazilbash, Qaiser Bashir, Sairah Ahmed, Uday Popat, Chitra Hosing, Issa Khouri, Elizabeth J Shpall, Richard E Champlin, Stefan O Ciurea
JournalBritish journal of haematology (Br J Haematol) Vol. 173 Issue 3 Pg. 444-55 (05 2016) ISSN: 1365-2141 [Electronic] England
PMID26947769 (Publication Type: Journal Article)
Copyright© 2016 John Wiley & Sons Ltd.
Chemical References
  • Cyclophosphamide
  • Mycophenolic Acid
  • Tacrolimus
Topics
  • Adult
  • Aged
  • Cyclophosphamide (therapeutic use)
  • Female
  • Graft Survival (immunology)
  • Graft vs Host Disease (immunology, prevention & control)
  • Hematopoietic Stem Cell Transplantation (methods)
  • Histocompatibility (immunology)
  • Humans
  • Male
  • Middle Aged
  • Mycophenolic Acid (therapeutic use)
  • Premedication (methods)
  • Retrospective Studies
  • Tacrolimus (therapeutic use)
  • Unrelated Donors
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: